Austco Healthcare's Growth Run Meets A Shrinking Order Book

Fund managers say supply chain delays have pushed pipeline conversion into FY27 after a year of rapid acquisition-led growth

30 Jun 2026 · 5 min read

A run of double-digit growth updates through 2025 came to an abrupt halt for Austco Healthcare in June 2026. DMX Asset Management said the nurse call and clinical workflow software provider fell 18 per cent after reporting a weaker second half of earnings, citing semiconductor supply chain disruption, longer freight transit times and hospital construction delays affecting the timing of its sales. The manager said it believed these represented delayed rather than lost opportunities, with installation timing and pipeline conversion shifting into FY27, but acknowledged that a deteriorating order book was also weighing on sentiment.

That order book concern had already surfaced in Austco's February 2026 half-year result. Merewether Capital reported revenue up 31 per cent to $48.2 million and net profit up 62 per cent to $4.8 million, keeping the company on track for $11 million to $12 million in full-year net profit against an enterprise value of roughly $115 million, but flagged that contracted backlog had fallen from $55 million at the October AGM update to $47 million. The manager cautioned that while Austco is not a traditional contracting business where backlog is a direct proxy for future revenue, it does provide a useful baseline, and it hoped the company could win one or two large hospital contracts to lift the backlog back toward record levels.

While AHC is not a traditional contracting business where the contract backlog is a direct proxy to future revenue, it does provide a baseline and hopefully they can win one or two large hospital contracts to see the backlog climb back to record highs.

— Merewether Capital, Monthly Report, February 2026

The growth story that built the thesis

Before the supply chain and backlog issues emerged, the commentary on Austco had been almost uniformly bullish. Tamim Funds Management reported in October 2025 that first-quarter FY26 revenue rose 51 per cent to $23.2 million, with EBITDA reaching $4.2 million at an 18.1 per cent margin, up from 16.0 per cent at the end of FY25, and unfilled contracted revenue standing at $54.6 million. The manager said the improving margin reflected genuine operating leverage as the company scaled, and pointed to the ageing population and rising demand for integrated communication and workflow systems in hospitals and aged care as a structural tailwind, adding that Austco's combination of strong intellectual property, high customer retention and expanding margins made it an attractive target for global healthcare technology distributors.

The company's recent performance reinforces this trend. First quarter revenue grew fifty one percent to twenty three point two million dollars... Margin expansion of this sort indicates that operating leverage is beginning to flow through the business.

— Tamim Funds Management, Article, November 2025

That growth traced back to a series of acquisitions completed through 2024 and 2025. DMX Asset Management described FY25 as a transformative year in its July 2025 monthly report, with revenue up around 40 per cent to more than $80 million and EBITDA up roughly 60 per cent to $13 million, helped by a full-year contribution from the Amenco acquisition. The manager said Austco was entering FY26 on track to deliver revenue in excess of $100 million and net profit after tax above $10 million, supported by a record order book of $55 million at 30 June 2025.

What managers are watching next

With management describing the recent delays as timing issues rather than lost business, and pipeline conversion pushed into FY27, the near-term test for Austco is whether the order book stabilises and grows again from its reduced $47 million level, and whether the semiconductor and hospital construction disruptions DMX Asset Management flagged in June 2026 prove as temporary as the company suggests.